文献速递胸部肿瘤

二甲双胍联合放化疗治疗局部晚期非小细胞肺癌的随机临床试验

Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

OCOG-ALMERA 2期随机试验因入组缓慢提前终止,54例无糖尿病局部晚期非小细胞肺癌患者随机接受放化疗±二甲双胍2000mg/d。

要点

  • 二甲双胍组1年PFS率34.8%,对照组63.0%(HR 2.42,95%CI 1.14-5.10)。
  • 二甲双胍组1年OS率47.4%,对照组85.2%(HR 3.80,95%CI 1.49-9.73)。

核心结论

  • 在无糖尿病的局部晚期非小细胞肺癌患者中,放化疗联合二甲双胍较单纯放化疗疗效更差且毒性增加。
  • 研究者不推荐对适合放化疗的局部晚期非小细胞肺癌患者使用二甲双胍。

研究设计与样本

  • OCOG-ALMERA为多中心2期随机临床试验,计划入组96例不可切除局部晚期非小细胞肺癌且无糖尿病患者。
  • 实际2014年9月24日至2019年3月8日随机54例(试验组26例,对照组28例),因入组缓慢提前终止。
  • 按IIIA vs IIIB期及是否接受巩固化疗分层,主要终点为12个月内治疗失败事件比例。

主要发现

  • 1年无进展生存率二甲双胍组34.8%(95%CI 16.6%-53.7%),对照组63.0%(95%CI 42.1%-78.1%),HR 2.42(95%CI 1.14-5.10)。
  • 1年总生存率二甲双胍组47.4%(95%CI 26.3%-65.9%),对照组85.2%(95%CI 65.2%-94.2%),HR 3.80(95%CI 1.49-9.73)。
  • 二甲双胍组53.8%报告至少1项≥3级不良事件,对照组25.0%。

关键数值与推荐

  • 二甲双胍用法为2000 mg/d,同步放化疗期间及之后持续最长12个月。
  • 放疗剂量为胸部60-63 Gy,化疗为铂类为基础方案,可联合或不联合巩固化疗。

临床怎么用

  • 对于拟接受根治性放化疗的局部晚期非小细胞肺癌患者,不应常规加用二甲双胍。
  • 该结果不支持在此人群中开展二甲双胍联合放化疗的进一步研究。

局限性

  • 试验因入组缓慢提前终止,实际样本量仅54例,低于计划的96例。
  • 为2期随机试验,统计效能有限,生存分析结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Unresected locally advanced non-small cell lung cancer (LA-NSCLC) shows poor survival outcomes even after aggressive concurrent chemoradiotherapy. Whether metformin, a diabetes agent that inhibits the mitochondria oxidative phosphorylation chain, could improve radiotherapy and chemotherapy response in LA-NSCLC remains to be studied. OBJECTIVE: To examine whether metformin, given concurrently with chemoradiotherapy and as consolidation treatment, could improve outcomes in patients with LA-NSCLC. DESIGN, SETTING, AND PARTICIPANTS: The Ontario Clinical Oncology Group Advanced Lung Cancer Treatment With Metformin and Chemoradiotherapy (OCOG-ALMERA) study was a multicenter phase 2 randomized clinical trial. Patients were stratified for stage IIIA vs IIIB LA-NSCLC and use of consolidation chemotherapy. The trial was designed to enroll 96 patients with unresected LA-NSCLC who did not have diabetes. The trial was conducted from September 24, 2014, to March 8, 2019. INTERVENTIONS: Patients were randomized to platinum-based chemotherapy, concurrent with chest radiotherapy (60-63 Gy), with or without consolidation chemotherapy or the same treatment plus metformin, 2000 mg/d, during chemoradiotherapy and afterward for up to 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients who experienced a failure event (ie, locoregional disease progression, distant metastases, death, and discontinuation of trial treatment or planned evaluations for any reason within 12 months). Proportions were compared using a 2-sided Fisher exact test. Conventional progression-free and overall survival were estimated using the Kaplan-Meier method. Adverse events were graded with Common Terminology Criteria for Adverse Events, version 4.03. All randomized patients were included in an intention-to-treat analysis. RESULTS: The trial was stopped early due to slow accrual. Between 2014 and 2019, 54 patients were randomized (26 in experimental arm and 28 in control arm). Participants included 30 women (55.6%); mean (SD) age was 65.6 (7.6) years. Treatment failure was detected in 18 patients (69.2%) receiving metformin within 1 year vs 12 (42.9%) control patients (P = .05). The 1-year progression-free survival rate was 34.8% (95% CI, 16.6%-53.7%) in the metformin arm and 63.0% (95% CI, 42.1%-78.1%) in the control arm (hazard ratio, 2.42; 95% CI, 1.14-5.10) The overall survival rates were 47.4% (95% CI, 26.3%-65.9%) in the metformin arm and 85.2% (95% CI, 65.2%-94.2%) in the control arm (hazard ratio, 3.80; 95% CI, 1.49-9.73). More patients in the experimental arm vs control arm (53.8% vs 25.0%) reported at least 1 grade 3 or higher adverse event. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the addition of metformin to chemoradiotherapy was associated with worse treatment efficacy and increased toxic effects compared with combined modality therapy alone. Metformin is not recommended in patients with LA-NSCLC who are candidates for chemoradiotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02115464.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tsakiridis T, Pond GR, Wright J, et al. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34323924. doi:10.1001/jamaoncol.2021.2328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。